While expectations are growing that Takeda Pharmaceutical Co. Ltd. will formally bid to acquire Shire PLC, market analysts are feverishly modeling all the options, and in addition to increasing odds for mega-merger specialist Pfizer Inc., at least one analyst is making a solid case for Amgen Inc. to buy out the Irish specialty pharma.
Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray
Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.